PURPOSE: To determine the vitreous concentration of complement fragment C5a in patients with proliferative diabetic retinopathy (PDR) and the relation between C5a and inflammatory cytokines including vascular endothelial growth factor (VEGF) and monocyte chemotactic protein-1 (MCP-1). METHODS: Vitreous samples were obtained at the time of vitrectomy from 12 eyes of 11 PDR patients and from 11 eyes of 11 patients without diabetes with macular disease (controls). Vitreous and serum concentrations of human C5a, VEGF, and MCP-1 were quantified using FACS Caliber flow cytometer. RESULTS: Vitreous concentration of C5a increased significantly in patients with PDR [median (range): 928.7 (46.6 to 3,319.4) pg/ml] compared with controls [58.7 (22.2 to 1,432.4) pg/ml; p < 0.01]. In PDR patients, vitreous concentration of C5a correlated significantly with those of VEGF (p < 0.05) and MCP-1 (p < 0.05). CONCLUSIONS: Our results suggest that C5a may play an important role in the pathogenesis of PDR and work in concert with inflammatory cytokines such as VEGF and MCP-1 in pathological angiogenesis.
PURPOSE: To determine the vitreous concentration of complement fragment C5a in patients with proliferative diabetic retinopathy (PDR) and the relation between C5a and inflammatory cytokines including vascular endothelial growth factor (VEGF) and monocyte chemotactic protein-1 (MCP-1). METHODS: Vitreous samples were obtained at the time of vitrectomy from 12 eyes of 11 PDR patients and from 11 eyes of 11 patients without diabetes with macular disease (controls). Vitreous and serum concentrations of humanC5a, VEGF, and MCP-1 were quantified using FACS Caliber flow cytometer. RESULTS: Vitreous concentration of C5a increased significantly in patients with PDR [median (range): 928.7 (46.6 to 3,319.4) pg/ml] compared with controls [58.7 (22.2 to 1,432.4) pg/ml; p < 0.01]. In PDR patients, vitreous concentration of C5a correlated significantly with those of VEGF (p < 0.05) and MCP-1 (p < 0.05). CONCLUSIONS: Our results suggest that C5a may play an important role in the pathogenesis of PDR and work in concert with inflammatory cytokines such as VEGF and MCP-1 in pathological angiogenesis.
Authors: A Accardo-Palumbo; G Triolo; G Colonna-Romano; M Potestio; M Carbone; A Ferrante; E Giardina; G Caimi; G Triolo Journal: Diabetologia Date: 2000-08 Impact factor: 10.122
Authors: Daniel N Cortright; Robin Meade; Stephen M Waters; Bertrand L Chenard; James E Krause Journal: Curr Eye Res Date: 2009-01 Impact factor: 2.424
Authors: Jayakrishna Ambati; Akshay Anand; Stefan Fernandez; Eiji Sakurai; Bert C Lynn; William A Kuziel; Barrett J Rollins; Balamurali K Ambati Journal: Nat Med Date: 2003-10-19 Impact factor: 53.440
Authors: Lijia Cheng; Hong Bu; Jose-Andres C Portillo; Yan Li; Carlos S Subauste; Suber S Huang; Timothy S Kern; Feng Lin Journal: Invest Ophthalmol Vis Sci Date: 2013-12-17 Impact factor: 4.799
Authors: Siva S R Iyer; Mollie K Lagrew; Stephanie M Tillit; Ramak Roohipourmoallai; Samuel Korntner Journal: Int J Mol Sci Date: 2021-07-01 Impact factor: 5.923
Authors: Ming Ming Yang; Jun Wang; Hong Ren; Yun Duan Sun; Jiao Jie Fan; Yan Teng; Yan Bo Li Journal: Mediators Inflamm Date: 2016-02-16 Impact factor: 4.711